Welcome to our dedicated page for ACCENDRA HEALTH INC/VA/ SEC filings (Ticker: ACH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ACCENDRA HEALTH INC/VA/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ACCENDRA HEALTH INC/VA/'s regulatory disclosures and financial reporting.
Accendra Health, Inc. has filed a shelf registration to offer up to $200,000,000 of common stock, preferred stock, debt securities, depositary shares, warrants, stock purchase contracts and units, which may be sold from time to time in one or more offerings.
Authorized capital stock consists of 200,000,000 common shares with $2.00 par value and 10,000,000 cumulative preferred shares with $100.00 par value; 76,583,702 common shares were outstanding as of March 31, 2026. The common stock trades on the NYSE under “ACH,” with a July 14, 2026 closing price of $3.61. Net proceeds from future sales are expected to be used for general corporate and working capital purposes. The filing also details Virginia-law and charter-based provisions, including control share and affiliated transaction statutes and board powers over preferred stock, that may make takeovers or changes in control more difficult.
Accendra Health, Inc. reports the expiration and final results of its exchange offers for its 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders tendered approximately $478.3 million of 2029 Notes and $548.0 million of 2030 Notes, representing about 99.9% and 99.2% of the amounts outstanding at launch. After cancellation of exchanged notes, $338,000 of 2029 Notes and $4,170,000 of 2030 Notes remained outstanding. In connection with the exchanges and a new money issuance, the company issued $213.0 million of First Lien Notes and $698.1 million of Second Lien Notes for existing notes, plus $326.25 million of new money First Lien Notes, for a total of $539.25 million First Lien Notes.
Accendra Health, Inc. is executing a major liability management transaction, exchanging nearly all of its unsecured senior notes for new, higher-coupon secured notes and putting new credit facilities in place. As of the early exchange deadline, holders tendered approximately $478.3 million of 4.500% notes due 2029 (about 99.9% outstanding) and $547.9 million of 6.625% notes due 2030 (about 99.2% outstanding). The company accepted and cancelled these notes and issued $213.0 million of 9.000% First Lien Notes due 2032 and $698.0 million of 9.750% Second Lien Notes due 2033, plus $326.25 million of new-money First Lien Notes, for a total of $539.25 million First Lien Notes. Only $363,000 of 2029 notes and $4.257 million of 2030 notes remain outstanding. Accendra also replaced its existing revolver with a new $300.0 million revolving credit facility due 2030 and amended its term loan to waive mandatory prepayments on $400.0 million of asset sale proceeds and to permit the new secured notes and related liens, all subject to leverage and interest coverage covenants.
Accendra Health, Inc. has launched exchange offers and related consent solicitations for its outstanding 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders can swap these unsecured notes into newly issued 9.000% senior secured first lien notes due 2032 and 9.750% senior secured second lien notes due 2033, with different consideration levels depending on participation in a new money notes issuance and early tender deadlines. The company is also raising $326.25 million in new first lien notes for cash and seeking consents to strip most covenants and certain events of default from the existing indentures. Accendra notes the offers are subject to multiple conditions and warns that failing to complete these or alternative transactions on favorable terms could materially adversely affect its financial condition.
Accendra Health EVP and General Counsel Heath H. Galloway reported a routine tax-related share disposition. On May 18, 2026, 1,822 shares of Accendra Health common stock were surrendered at $2.91 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold in the open market. After this transaction, Galloway directly holds 166,306 shares of Accendra Health common stock, showing he retains a substantial equity stake following the tax withholding event.
Accendra Health EVP & CFO Jonathan A. Leon reported a small share disposition related to taxes rather than an open-market trade. On May 15, 2026, he surrendered 1,770 shares of Common Stock at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this tax-withholding transaction, he directly held 290,533 shares of Accendra Health common stock.
Accendra Health President and CEO Edward A. Pesicka surrendered 17,692 shares of common stock on May 15, 2026 to cover tax withholding obligations tied to vesting of restricted stock. These shares were delivered back to the company rather than sold on the open market. Following this routine tax-withholding disposition, he directly holds 1,072,785 common shares.
Accendra Health Inc. executive Heath H. Galloway reported a routine tax-related share disposition. On this Form 4, 966 shares of common stock were surrendered to the company at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this non-market transaction, Galloway directly holds 168,128 common shares.
Accendra Health Inc. executive Perry A. Bernocchi, EVP and Chief Operating Officer, reported a routine tax-related share disposition. On May 15, 2026, he surrendered 7,908 shares of common stock at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this non-market transaction, he directly holds 313,913 shares of Accendra Health common stock.